| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
18,057 |
16,997 |
$2.18M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
24,135 |
22,861 |
$2.03M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
10,058 |
9,448 |
$1.40M |
| 0225U |
|
2,626 |
2,484 |
$1.00M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,223 |
1,123 |
$722K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
4,793 |
4,563 |
$719K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,885 |
3,693 |
$640K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
12,819 |
11,951 |
$399K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
7,733 |
6,932 |
$360K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
6,062 |
5,434 |
$346K |
| 71045 |
Radiologic examination, chest; single view |
9,401 |
8,861 |
$326K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,160 |
3,810 |
$269K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
11,558 |
10,719 |
$260K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,073 |
2,950 |
$204K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
29,081 |
25,731 |
$189K |
| 80053 |
Comprehensive metabolic panel |
25,553 |
22,707 |
$184K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
6,640 |
6,265 |
$171K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,245 |
3,286 |
$138K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
3,639 |
1,279 |
$98K |
| 84484 |
|
10,227 |
9,164 |
$89K |
| 71046 |
Radiologic examination, chest; 2 views |
1,865 |
1,819 |
$86K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
356 |
336 |
$75K |
| 83880 |
|
3,110 |
2,960 |
$71K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,708 |
2,496 |
$70K |
| 87631 |
|
830 |
821 |
$70K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,721 |
1,616 |
$68K |
| 81025 |
|
7,294 |
6,777 |
$59K |
| 83735 |
|
10,079 |
9,422 |
$57K |
| 83690 |
|
6,681 |
6,220 |
$43K |
| 81001 |
|
13,789 |
12,949 |
$41K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
779 |
748 |
$37K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
521 |
498 |
$36K |
| 87088 |
|
3,525 |
3,342 |
$31K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,642 |
2,340 |
$29K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
997 |
939 |
$28K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
376 |
362 |
$24K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
49 |
44 |
$23K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,731 |
1,631 |
$22K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
84 |
81 |
$21K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
545 |
509 |
$20K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
351 |
208 |
$19K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
3,542 |
2,660 |
$17K |
| J3490 |
Unclassified drugs |
3,207 |
2,580 |
$16K |
| 85610 |
|
5,484 |
5,187 |
$15K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
643 |
626 |
$15K |
| 82962 |
|
5,790 |
5,274 |
$13K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
313 |
308 |
$12K |
| 87040 |
|
838 |
803 |
$10K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,535 |
3,284 |
$10K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
267 |
249 |
$8K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,027 |
957 |
$8K |
| 81003 |
|
2,874 |
2,684 |
$7K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
129 |
46 |
$7K |
| 83605 |
|
736 |
675 |
$7K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
204 |
189 |
$7K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
24 |
24 |
$6K |
| 82728 |
|
610 |
585 |
$6K |
| 87430 |
|
377 |
364 |
$5K |
| 84466 |
|
576 |
552 |
$5K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,369 |
2,158 |
$5K |
| 94664 |
|
172 |
164 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
173 |
162 |
$4K |
| 74022 |
|
69 |
66 |
$4K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
58 |
58 |
$3K |
| 97161 |
|
116 |
113 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
1,924 |
1,293 |
$3K |
| 83540 |
|
576 |
552 |
$3K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
14 |
13 |
$3K |
| 82607 |
|
244 |
239 |
$2K |
| 82077 |
|
1,296 |
1,162 |
$2K |
| 85730 |
|
363 |
337 |
$2K |
| 84702 |
|
169 |
151 |
$2K |
| 87081 |
|
222 |
216 |
$1K |
| 87590 |
|
63 |
60 |
$1K |
| 87077 |
|
149 |
144 |
$1K |
| 85652 |
|
363 |
342 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
204 |
193 |
$976.68 |
| 82746 |
|
101 |
99 |
$926.58 |
| 87807 |
|
60 |
60 |
$699.72 |
| 85379 |
|
90 |
89 |
$664.01 |
| 87070 |
|
73 |
70 |
$654.53 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
138 |
135 |
$652.98 |
| 86769 |
|
28 |
28 |
$568.02 |
| 87186 |
|
57 |
55 |
$559.92 |
| 82565 |
|
134 |
123 |
$475.47 |
| V2632 |
Posterior chamber intraocular lens |
57 |
57 |
$474.60 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
256 |
239 |
$447.24 |
| 85027 |
|
67 |
64 |
$419.81 |
| 96376 |
|
14 |
14 |
$411.91 |
| 85007 |
|
138 |
132 |
$351.32 |
| 80076 |
|
44 |
41 |
$309.69 |
| 96367 |
|
13 |
12 |
$251.64 |
| 87015 |
|
31 |
31 |
$241.28 |
| 0352U |
|
12 |
12 |
$237.86 |
| 83921 |
|
12 |
12 |
$211.34 |
| C9113 |
Injection, pantoprazole sodium, per vial |
38 |
36 |
$111.02 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
16 |
14 |
$108.84 |
| 82248 |
|
28 |
28 |
$105.70 |
| 99199 |
Unlisted special service, procedure or report |
13 |
13 |
$65.00 |
| 83615 |
|
15 |
15 |
$63.24 |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
798 |
647 |
$47.77 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
26 |
24 |
$45.92 |
| 84100 |
|
16 |
13 |
$41.37 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
12 |
12 |
$38.55 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
35 |
30 |
$28.63 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
15 |
14 |
$15.26 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
14 |
12 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
14 |
12 |
$0.00 |